FDA Puts Speed Breaker On Novavax's COVID/Flu Combo Shot Trial On Concerns Related To Damaged Nerves
Novavax Inc. (NASDAQ:NVAX) stock is trading lower on Wednesday. The FDA has placed a clinical hold on Novavax’s Investigational New Drug (IND) application for its COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.
FDA Puts Clinical Hold On Novavax COVID-19-Influenza Combo Vaccine Candidate; Stock Tumbles
Wednesday said the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its COVID-19-Influenza
Novavax stock plunges as FDA puts clinical hold on COVID-flu combo vaccine
Novavax shares plummet 30% as FDA places clinical hold on COVID-19 and influenza combination vaccine due to serious adverse event.
US FDA pauses Novavax's trial of combo COVID-flu shot on safety concerns
The U.S. Food and Drug Administration has put on hold a trial of Novavax's COVID-influenza and its standalone flu vaccines after a participant who took the combination shot reported nerve damage, the company said on Wednesday.
Novavax Says FDA Puts Clinical Hold on Covid-19, Flu Vaccines
Novavax said federal regulators put a clinical hold on its application for a combination Covid-19 and influenza vaccine and standalone flu inoculation, sending shares down sharply.
Novavax says FDA put hold on combination Covid-flu shot and influenza vaccine; shares plunge
The so-called clinical hold is due to a single report of nerve damage in a patient who received the combination shot in a phase two trial.
Novavax shares sink as US FDA puts trial of combo COVID-flu vaccine on hold
Shares in Novavax (NASDAQ:NVAX) slumped in premarket US trading on Wednesday after the US Food and Drug Administration placed a trial of its experimental COVID-19 and influenza vaccine combination on hold.
SchaeffersResearch.com1h
3 Vaccine Stocks to Watch as Flu Season Approaches
Flu season is almost here, and there is a respiratory syncytial virus (RSV) vaccine update worth monitoring. Earlier today, ...
bovnews1d
Why Did Novavax Inc (NVAX) Stock See -17.13% Plunge in the Last 90 Days?
On Friday, Novavax Inc (NVAX) stock saw a decline, ending the day at $12.53 which represents a decrease of $-0.37 or -2.87% from the prior close of $12.9. The stock opened at $12.72 and touched a low ...
Buy Rating Affirmed for Novavax Amid Strategic Alliances and Promising Vaccine Trials
Novavax (NVAX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mayank Mamtani ...
Finanznachrichten3h
Novavax, Inc.: Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
GAITHERSBURG, Md., Oct. 16, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M adjuvant, today announced that the U.S. Food and ...
Nasdaq5d
Novavax (NVAX) Advances While Market Declines: Some Information for Investors
The most recent trading session ended with Novavax (NVAX) standing at $12.91, reflecting a +1.77% shift from the previouse trading day's closing. The stock exceeded the S&P 500, which registered a ...
bovnews12d
Novavax Inc (NVAX) Stock: Surpassing Expectations in the Market?
On Thursday, Novavax Inc (NVAX) stock saw a decline, ending the day at $14.42 which represents a decrease of $-0.26 or -1.77% from the prior close of $14.68. The stock opened at $14.07 and touched a ...
ETF Daily News6d
Novavax (NASDAQ:NVAX) Stock Price Up 3.4% – Still a Buy?
Shares of Novavax, Inc. (NASDAQ:NVAX – Get Free Report) shot up 3.4% during mid-day trading on Tuesday . The company traded as high as $13.54 and last traded at $13.46. 1,167,174 shares traded ...
Novavax Inc (NVAX) Q2 2024 Earnings Call Highlights: Strategic Partnerships and Financial ...
Novavax Inc (NVAX) reports significant revenue from Sanofi partnership and outlines strategic shifts to enhance future growth ...